SCHEMBL375006

SCHEMBL375006

O=C(c1nc[nH]n1)N(Cc1ccc(OC(F)F)c(OC(F)F)c1)C1CCOCC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 10/20 0.39
PDE4A P27815 6/20 0.39
PDE4B Q07343 6/20 0.39
PDE4C Q08493 6/20 0.39
SLC6A9 P48067 2/20 0.35
SLC6A5 Q9Y345 1/20 0.35
REN P00797 4/20 0.35
KCNH2 Q12809 1/20 0.34
LMNA P02545 2/20 0.34
MAPT P10636 1/20 0.34
THRB P10828 1/20 0.34
ALDH1A1 P00352 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
RAB9A P51151 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
HTR2A P28223 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL374840 0.87 SLC6A9 (0.41) SLC6A9SLC6A5KCNH2
SCHEMBL375116 0.83 KDM4E (0.40) SLC6A9SLC6A5KCNH2ALDH1A1RAB9A
SCHEMBL375173 0.83 SLC6A9 (0.42) SLC6A9SLC6A5RENKCNH2LMNA
SCHEMBL375110 0.83 SLC6A9 (0.53) SLC6A9SLC6A5RENKCNH2LMNA
SCHEMBL375594 0.82 KCNH2 (0.39) SLC6A9SLC6A5KCNH2KMT2A
SCHEMBL374833 0.81 SLC6A9 (0.39) SLC6A9SLC6A5RENKCNH2
SCHEMBL375305 0.81 SLC6A9 (0.36) SLC6A9SLC6A5KCNH2ALDH1A1TSHR
SCHEMBL375432 0.81 EPHX1 (0.39) SLC6A9SLC6A5KCNH2HTR2A
SCHEMBL375183 0.81 SLC6A9 (0.40) SLC6A9SLC6A5RENKCNH2HTR2A
SCHEMBL375145 0.81 SLC6A4 (0.49) KCNH2LMNAMAPTTHRBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8623898-B2 Glycine transporter inhibiting substances TAISHO PHARMACEUTICAL CO., LTD. (JP) 2014-01-07 US disclosed
EP-2409976-A1 GLYCINE TRANSPORTER INHIBITOR Taisho Pharmaceutical Co., Ltd. (JP) 2012-01-25 EP disclosed
US-20120010414-A1 GLYCINE TRANSPORTER INHIBITING SUBSTANCES TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010414-A1 GLYCINE TRANSPORTER INHIBITING SUBSTANCES SLC18A2, SLC1A2, SLC6A1 PDE4D 2429/4885PDE4A 2697/4885PDE4B 2380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.